Esperion Therapeutics | ESPR - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 695M 1.12B 2026-03
Alnylam Pharmaceuticals USD 205.99M 19.57M 2026-03
Alterity Therapeutics Limited AUD -6.3M 525.41K 2025-12
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 1.82B 486M 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Cipla INR 5.55B 1.21B 2026-03
CSL USD 401M 96.5M 2025-12
Cytokinetics USD -206.03M 23M 2026-03
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Geron USD -3.64M 27.5M 2026-03
Grifols EUR 114.37M 34.03M 2025-12
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
Merck USD -4.24B 7.2B 2026-03
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Moderna USD -1.34B 517M 2026-03
Nektar Therapeutics USD -36.08M 978K 2025-12
Pfizer USD 2.69B 4.34B 2026-03
PTC Therapeutics USD -2.81M 132.16M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Sanofi EUR 1.61B 2.42B 2026-03
Sarepta Therapeutics USD 330.96M 743.18M 2026-03
United Therapeutics USD 274.9M 89.4M 2026-03
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12